ArticleOpen forum infectious diseases2025
A Longitudinal Description of the Health-Related Quality of Life Among Individuals at High Risk After SARS-CoV-2 Infection: A Dutch Multicenter Observational Cohort Study.
Article in Open forum infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05195060 (The Dutch Cohort Study for the Evaluation of the Use of Neutralizing Monoclonal Antibodies and Other Antiviral Agents Against SARS-CoV-2), which is not on this map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Dutch Cohort Study for the Evaluation of the Use of Neutralizing Monoclonal Antibodies and Other Antiviral Agents Against SARS-CoV-2
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Health-related quality of life in COVID-19 patients: a systematic review and meta-analysis of EQ-5D studies.Health and quality of life outcomes · 2025Pooled it
- Impact of post-exertional malaise frequency and fatigue in Long COVID patients on health-related quality of life.Health and quality of life outcomes · 2026Article
- Symptom Alleviation/Resolution and Returns to Usual Health/Activities in Immunocompromised Adults with COVID-19 Treated with Nirmatrelvir-Ritonavir: Results from the EPIC-IC Trial.Infectious diseases and therapy · 2025Article
- Cost-effectiveness Analysis of Nirmatrelvir/Ritonavir for COVID-19 Among Individuals at High Risk: A Modeling Study.Open forum infectious diseases · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Health-related quality of life (HRQoL) data post-COVID-19 in patients with medical conditions associated with severe disease are lacking. Here, we assess the longitudinal impact of COVID-19 on HRQoL and employment status in individuals at high risk. Methods: This multicenter prospective cohort study included individuals at high risk for severe disease who were hospitalized or not-hospitalized with SARS-CoV-2 infection (September 2021-February 2024). Questionnaires about HRQoL and employment status were collected at 3, 6, and 12 months post-COVID-19 and retrospectively recalled and reported for pre-COVID-19. With a mixed effects model, we assessed the course of and risk factors for changes in HRQoL utility score. Results: Among 332 individuals (median age, 59.8 years [IQR, 48.8-67.1]; 50.6% female), 184 (55.4%) were hospitalized for COVID-19 (intensive care unit admission, 12.0%). High-risk factors included solid organ transplantation (19.6%), hematologic malignancies (28.0%), and immunosuppressive medication use (56.6%). The median HRQoL utility score declined from 0.85 (IQR, 0.74-1.00) pre-COVID-19 to 0.81 (0.70-0.92) 12 months post-COVID-19 ( Conclusions: Solid organ transplant recipients and individuals requiring oxygen therapy experience a substantial HRQoL decline over 12 months post-COVID-19. Moreover, almost half of employed participants reported COVID-19-related sick leave, correlating with lower HRQoL. This highlights the continuous burden of COVID-19 for this vulnerable population and supports the implementation of preventive approaches.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.